Role slzného filmu v refrakci: Kvantitativní hodnocení před a po terapii na přístroji Rexon-Eye

Česká verze

Authors: Veronika Stankovičová ¹; Viktor Ladislav Nováček ¹; Pavel Rozsíval ^1,2,3
Authors place of work: Ophthalmology Department, Institute of Aviation Medicine, Prague, Czech Republic ¹; Charles University, Faculty of Medicine in Hradec Králové, Czech Republic ²; Department of Ophthalmology, Eye Clinic of the University Hospital Hradec Králové, Czech Republic ³
Published in the journal: Čes. a slov. Oftal., 82, 2026, No. 4, p. 190-194
Category: Původní práce
doi: https://doi.org/10.31348/2026/3

Summary

Aim: The aim of this study was to assess the effect of Rexon-Eye therapy, based on quantum molecular resonance (QMR) technology, optical parameters, tear film stability, and patients’ subjective symptoms.

Material and Methods: A total of 30 patients (20 women, mean age 64.9 years; 10 men, mean age 64.6 years) diagnosed with dry eye syndrome were included in the study. Common systemic comorbidities were recorded, most frequently arterial hypertension, hypercholesterolemia, thyroid disorders, type 2 diabetes mellitus, and hyperuricemia. Each patient underwent four treatment sessions (once weekly for 20 minutes) according to the manufacturer’s recommended protocol. Objective parameters –⁠ including objective scatter index (OSI), modulation transfer function cutoff (MTF cutoff), potential visual acuity (PVA), and vision break-up time (VBUT) –⁠ were assessed using the HD Analyzer before therapy and again 1 to 3 months after treatment completion. Subjective symptoms were evaluated using the standardized Ocular Surface Disease Index (OSDI) questionnaire.

Results: No statistically significant changes were observed in OSI, MTF cutoff, or PVA. VBUT remained unchanged. By contrast, OSDI scores improved both statistically and clinically significantly.

Conclusion: QMR therapy with the Rexon-Eye device led to significant improvement in subjective symptoms, while objective optical quality parameters showed no statistically significant changes. QMR therapy appears to be a safe and well-tolerated method that may expand therapeutic options in clinical practice.

Keywords:

Visual acuity – tear film – dry eye syndromes – optical quality – Rexon-eye therapy

Zdroje

1. Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II Definition and classification report. Ocul Surf. 2017 Jul;15(3):276-283.

2. Montes-Mico R, Belda JI, Albarrán-Diego C, Charman WN, Cerviño A. Postblink changes in total and corneal optical aberrations in dry eye. Cornea. 2004 Oct;23(7):689-694.

3. Saad A, Gatinel D. Topographie et aberrations de haut ordre dans la sécheresse oculaire [Topography and higher order aberrations in dry eye disease]. J Fr Ophtalmol. 2012 Jun;35(6):413-418. French.

4. Zemanová E, Baranová J, Jirásková N, et al. Syndrom suchého oka –⁠ přehled. Čes a slov Oftalmol. 2021;77(2):63-71.

5. Qiao L, Cai X, Wan X, et al. Feasibility of optical quality analysis system for the objective evaluation of accommodation. BMC Ophthalmol. 2020;20(1):254.

6. Comment on “Objective Optical Quality With Multifocal Intraocular Lenses”. Asia Pac J Ophthalmol (Phila). 2022 Nov;11(6):e1.

7. Zafar A, Chu RC, Bishara MN, et al. Objective quantification of image quality and optical scatter before and after Nd:YAG capsulotomy using the HD Analyzer. Clin Ophthalmol. 2020;14 : 1231-1238.

8. Rexon-Eye: Resono [Internet]. Available from: https://www.resono. it/rexon-eye

9. Kamiya K, Shimizu K, Igarashi A, et al. Changes in optical quality and intraocular scattering after implantation of multifocal intraocular lenses. J Cataract Refract Surg. 2012;38(5):769-776.

10. Visiometrics launches HD Analyzer optical quality analysis system [Internet]. Optometry Times. 2013 Jun 10 [cited 2025 May 31]. Available from: https://www.optometrytimes.com/view/visiometrics -⁠ -launches-hd-analyzer-optical-quality-analysis-system

11. Sella S, Adami V, Amati E, et al. In vitro analysis of Quantum Molecular Resonance effects on human mesenchymal stromal cells. PLOS ONE. 2018;13(1):e0190082. doi:10.1371/journal.pone.0190082

12. Galliot A, Labetoulle M, Riancho L, et al. Effectiveness and safety of quantum molecular resonance electrotherapy for meibomian gland dysfunction: A pilot study. Eur J Ophthalmol. 2023 Mar;33(2):329-335.

13. Vigo L, Pellegrini M, Bernabei F, et al. Efficacy of intense pulsed light therapy in the treatment of meibomian gland dysfunction: a systematic review and meta-analysis. Ocul Surf. 2021;19 : 67-77.

14. Artal P, Benito A, Pérez GM, et al. An objective scatter index based on double-pass retinal images of a point source to classify cataracts. PLoS One. 2011;6(2):e16823.

15. Lee JH, Ahn JM, Kim EK, Seo KY, Kim TI. Optical quality and intraocular scattering in dry eye patients. Clin Ophthalmol. 2017;11 : 1433 -⁠ 1439.

16. Fernández J, Rodríguez-Vallejo M, Martínez Fernández I, et al. Optical quality after refractive surgery evaluated by double-pass technique. J Cataract Refract Surg. 2011;37(5):847-853.

17. Shemer A, Golan Y, Kresch T, et al. Randomized double-masked trial on quantum molecular resonance for dry eye. Cornea. 2024;43(1):45-52.

18. Ballesteros-Sánchez A, Rocha-de-Lossada C, Sánchez-González JM, Tedesco GR, Borroni D. Efficacy and safety of quantum molecular resonance electrotherapy in dry eye disease: a systematic review with meta-analysis. Ophthalmol Ther. 2025 May;14(5):1111-1131. doi:10.1007/s40123-025-01133-y